Astra Zeneca re-run, Lane’s credit concerns - a podcast by Phil Dobbie

Friday 27th November 2020

There are some questions over the numbers provided in phase three of the Astra Zeneca vaccine trial. NAB’s David de Garis says the concern is over the age of participations in the subset who achieved the highest level of efficiency. The makers claim a rerun of trials won’t slow progress, although some believe it could delay entry into the US. The ECB’s Philip Lane expressed concern about tightened of credit standards which could impede the European recovery. Meanwhile, lockdowns are being extended in parts of Europe. And on a quiet day in the markets, the pound is lower, with another day passing without any Brexit progress.

Further episodes of NAB Morning Call

Further podcasts by Phil Dobbie

Website of Phil Dobbie